Active Ingredient(s): Gadobenate Dimeglumine
FDA Approved: * November 23, 2004
Pharm Company: * BRACCO
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Multihance Overview

Gadobenic acid (INN, brand name Multihance) is a complex of gadolinium with the ligand BOPTA. In the form of the methylglucamine salt meglumine gadobenate (INNm) or gadobenate dimeglumine (USAN), it is used as a gadolinium-based MRI contrast medium.[3] BOPTA is a derivative of DTPA in which one terminal carboxyl group, –C(O)OH is replaced by -C–O–CH2C6H5. Thus gadobenic acid is closely related to gadopentetic acid. BOPTA itself was first synthesized in 1995.&...

Read more Multihance Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Multihance Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Gadobenate Dimeglumine
  • Injection: 10.58gm/20ml (529mg/ml), 2.645gm/5ml (529mg/ml), 26.45gm/50ml (529mg/ml), 5.29gm/10ml (529mg/ml), 52.9gm/100ml (529mg/ml), 7.935gm/15ml (529mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Multihance: (2 results)

Sorted by National Drug Code
  • 0270-5164 Multihance 529 mg/ml Intravenous Injection, Solution by Bracco Diagnostics Inc
  • 0270-5264 Multihance 529 mg/ml Intravenous Injection, Solution by Bracco Diagnostics Inc

Other drugs which contain Gadobenate Dimeglumine or a similar ingredient: (2 results)